Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | NA |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin (DDP) | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | epithelial ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | Microarray, qPCR, Western blot, in vitro knockdown, RIP |
| Sample | ovarian cancer cell lines HEY, A2780, A2780/DDP, HO8910, HO8910PM, SKOV3, SKOV3/ DDP, and normal human ovarian epithelial cell line IOSE, EOC tissues, normal ovarian tissues, EOC tissues, normal ovarian tissues |
| Expression Pattern | down-regulated |
| Function Description | lncRNA GAS5 to be dramatically low expressed in EOC samples and correlated with prognosis. Compared with sensitive cell lines, GAS5 was also low expressed in DDP resistant OC cell lines, and over-expression of GAS5 significantly enhanced the sensitivity of OC cells to DDP in vivo and in vitro. Meanwhile the overexpression of GAS5 also caused OC cells G0/G1 arrest and apoptosis increase. Mechanistically, GAS5 might regulate PARP1 expression by recruiting the transcription factor E2F4 to its promoter, and then affect the MAPK pathway activity. Due to the 5`TOP structure, GAS5 could be regulated by transcription inhibitor rapamycin in OC cells. |
| Pubmed ID | 31391118 |
| Year | 2019 |
| Title | Long non-coding RNA GAS5 inhibits DDPresistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4- PARP1-MAPK axis |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for epithelial ovarian cancer | OMIM COSMIC |